International industry media FirstWord Pharma recently unveiled its "Spotlight On: The Drugs That Will Shape 2026" list, providing an in-depth analysis of 20 key drugs poised to define the trajectory of the global pharmaceutical industry and transform disease treatment paradigms in 2026 and beyond.

Zhongshan-based company Akeso's Ivonescimab (PD-1/VEGF bispecific antibody) was selected for inclusion. It stands as the only drug on this list originating from a Chinese innovative pharmaceutical company's independent R&D.

Approved for market in 2024, Ivonescimab outperformed Merck's blockbuster Keytruda (pembrolizumab) in clinical trials, marking it as a global pioneer in bispecific antibody therapy.

Founded in 2012 in Zhongshan's Torch High-Tech Zone, Akeso has prioritized global clinical needs, anchoring its growth in technological self-reliance. The company continuously refines R&D/clinical strategies and expands its multi-layered drug innovation framework.